Multiple roles of cyclooxygenase-2 in endometrial cancer

Anticancer Research

Volumn 25, Issue 6 A, 2005, Pages 3679-3687

  Ohno, Satoshi ^a,b   Ohno, Yumiko ^b   Suzuki, Nobutaka ^b   Inagawa, Hiroyuki ^c,d,e   Kohchi, Chie ^d,e   Soma, Gen Ichiro ^d,e   Inoue, Masaki ^b  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c Applied Aquabiology   (Japan)

^d TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^e TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Angiogenesis; Apoptosis; Cell growth; COX 2; Endometrial cancer; Immunomodulation; Metastatic potential; Review

Indexed keywords

ANGIOGENIC FACTOR; ARACHIDONIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CD8 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 2; MATRIX METALLOPROTEINASE; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN G2; PROSTAGLANDIN H2; PROSTAGLANDIN SYNTHASE; PROTEIN BCL 2; PROTEIN KINASE B; THROMBOXANE A2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CONFERENCE PAPER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; DRUG SELECTIVITY; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; ENZYME INDUCTION; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MENSTRUAL CYCLE; METASTASIS POTENTIAL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR CELL;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CYCLOOXYGENASE 2; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 27844562734     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Sweeney CJ: Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol 26: S122-125, 2003.
2. Choy H and Milas L: Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 95: 1440-1452, 2003.
3. Saha D, Datta PK, Sheng H, Morrow JD, Wada M, Moses HL and Beauchamp RD: Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells. Neoplasia 1: 508-517, 1999.
4. 2 release in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 279: L201-207, 2000.
5. Mark KS, Trickier WJ and Miller DW: Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Ther 297: 1051-1058, 2001.
6. Jones MK, Szabo IL, Kawanaka H, Husain SS and Tarnawski AS: von Hippel Lindau tumor suppressor and HIF-1alpha: new targets of NSAIDs inhibition of hypoxia-induced angiogenesis. FASEB J 16: 264-266, 2002.
7. Schmedtje JF Jr, Ji YS, Liu WL, DuBois RN and Runge MS: Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells. J Biol Chem 272: 601-608, 1997.
8. Fossilen E: Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21, 2000.
9. Liu XH, Kirschenbaum A, Lu M, Yao S, Dosoretz A, Holland JF and Levine AC: Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J Biol Chem 277: 50081-50086, 2002.
10. Dohadwala M, Batra RK, Luo J, Lin Y, Krysan K, Pold M, Sharma S and Dubinett SM: Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 277: 50828-50833, 2002.
11. Vaday GG, Schor H, Rahat MA, Lahat N and Lider O: Transforming growth factor-beta suppresses tumor necrosis factor alpha-induced matrix metalloproteinase-9 expression in monocytes. J Leukoc Biol 69: 613-621, 2001.
12. Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L and Martin-Sanz P: Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33: 860-867, 2001.
13. Nor JE, Christensen J, Mooney DJ and Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154: 375-384, 1999.
14. Parfenova H, Parfenov VN, Shlopov BV, Levine V, Falkos S, Pourcyrous M and Leffler CW: Dynamics of nuclear localization sites for COX-2 in vascular endothelial cells. Am J Physiol Cell Physiol 281: C166-178, 2001.
15. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB and Lipsky PE: Cyclooxygenase in biology and disease. FASEB J 72:1063-1073, 1998.
16. Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A and Isner JM: Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97: 99-107, 1998.
17. Tsujii M and DuBois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83: 493-501, 1995.
18. Daniel TO, Liu H, Morrow JD, Crews BC and Marnett LJ: Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59: 4574-4577, 1999.
19. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y and Honn KV: Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochem Biophys Res Commun 267: 245-251, 2000.
20. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL and Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251, 1993.
21. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF and Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569, 2001.
22. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P and Ogier-Denis E: Celecoxib induces apoptosis by inhibiting 3-phosphoinositide- dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277:27613-27621, 2002.
23. Elder DJ, Halton DE, Playle LC and Paraskeva C: The MEK/ERK pathway mediates COX-2-selective NSAID-induced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer 99: 323-327, 2002.
24. Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 55: 362-366, 1998.
25. Cao Y and Prescott SM: Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 190: 279-286, 2002.
26. Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686, 1998.
27. Kimura M, Osumi S and Ogihara M: Stimulation of DNA synthesis and proliferation by prostaglandins in primary cultures of adult rat hepatocytes. Eur J Pharmacol 404: 259-271, 2000.
28. Sheng H, Shao J, Washington MK and DuBois RN: Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276: 18075-18081, 2001.
29. Tsujii M, Kawano S and DuBois RN: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94: 3336-3340, 1997.
30. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Fold M, Batra RK and Dubinett SM: Non-small cell lung cancer cyclooxygenase-2- dependent invasion is mediated by CD44. J Biol Chem 276: 20809-20812, 2001.
31. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC and Dubinett SM: Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164: 361-370, 2000.
32. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, Dohadwala M, Batra RK and Dubinett SM: Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res 9: 961-968, 2003.
33. Kojima M, Morisaki T, Uchiyama A, Doi F, Mibu R, Katano M and Tanaka M: Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann Surg Oncol 8: 458-465, 2001.
34. DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, Sterman DH and Albelda SM: Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res 63: 7845-7852, 2003.
35. Wu CY, Wang K, McDyer JF and Seder RA: Prostaglandin E2 and dexamethasone inhibit IL-12 receptor expression and IL-12 responsiveness. J Immunol 161: 2723-2730, 1998.
36. Harris SG, Padilla J, Koumas L, Ray D and Phipps RP: Prostaglandins as modulators of immunity. Trends Immunol 23: 144-150, 2002.
37. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, Mancuso S, Scambia G and Lauriola L: Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 95: 801-807, 2002.
38. Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R and Jones JG: Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 21: 147-154, 2002.
39. Jeon YT, Kang S, Kang DH, Yoo KY, Park IA, Bang YJ, Kim JW, Park NH, Kang SB, Lee HP and Song YS: Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev 13: 1538-1542, 2004.
40. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K and Miyazaki K: Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol 33: 213-219, 2002.
41. Uotila PJ, Erkkola RU and Klemi PJ: The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med 34: 428-433, 2002.
42. Ohno Y, Ohno S, Suzuki N, Kamei T, Inagawa H, Soma G and Inoue M: Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer 114: 696-701, 2005.
43. Toyoki H, Fujimoto J, Sato E, Sakaguchi H and Tamaya T: Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in uterine endometrial cancers. Ann Oncol 16: 51-55, 2005.
44. 2 in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 28: 1023-1031, 2001.
45. Landen CN Jr, Mathur SP, Richardson MS and Creasman WT: Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol 188: 1174-1176, 2003.
46. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58: 3491-3494, 1998.
47. Ohno S, Tachibana M, Shibakita M, Dhar DK, Yoshimura H, Kinugasa S, Kubota H, Masunaga R and Nagasue N: Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer. Ann Surg Oncol 7: 750-757, 2000.
48. Eerola AK, Soini Y and Pääkkö P: A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma. Clin Cancer Res 6: 1875-1881, 2000.
49. Schumacher K, Haensch W, Röefzaad C and Schlag PM: Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res 61: 3932-3936, 2001.
50. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H: Proliferative activity of intratumoral CD8+ T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61: 5132-5136, 2001.
51. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC and Coukos G: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213, 2003.